<DOC>
	<DOCNO>NCT00794716</DOCNO>
	<brief_summary>This study evaluate predictive value NRL972 pharmacokinetics diagnosis steatohepatitis use fatty liver disease comparator group . In addition , sensitivity specificity NRL972 pharmacokinetics diagnostic tool compare result standard laboratory test , elastography , test metabolic marker serum fibrosis marker frequently use evaluation clinically predict NAFLD patient . Patients include clinical evidence fatty liver disease refer clinic diagnostic work-up , include liver biopsy , blood test scan liver .</brief_summary>
	<brief_title>Pharmacokinetics NRL972 Patients With Nonalcoholic Steatohepatitis ( NASH ) Non-Alcoholic Fatty Liver Disease ( NAFLD )</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Subjects meet follow condition eligible enrollment : Males female ( female nonchildbearing potential childbearing potential take medically appropriate contraception ) Any ethnicity Age : 18 80 year age Clinical evidence nonalcoholic liver disease require conduct liver biopsy diagnosis NAFLD and/or stag disease severity Willing able provide inform consent Subjects fulfilling follow criterion exclude enrollment : General subject Presence acute chronic viral hepatitis confirm serology Clinical sign significant cholestasis Liver impairment due spaceoccupying process ( e.g . carcinoma ) Liver transplant recipient patient schedule liver transplantation Clinically evident rapidly deteriorate hepatic function Significant bleeding diathesis Esophageal bleeding within 8 week prior study entry Presence contraindication conduct plan liver biopsy ( e.g . allergy lidocaine , coagulopathy &lt; 100 x109/L thrombocyte and/or INR &gt; 1.3 History allergic reaction fluorescein Presence acute infection Previous participation trial Having receive investigational drug treatment within 30 day prior study entry require concurrent treatment experimental drug treatment Uncontrolled hypo hypertension ( treat untreated ) rest systolic blood pressure &gt; 160 &lt; 90 mmHg , diastolic blood pressure &gt; 95 &lt; 50 mmHg Clinically relevant abnormal laboratory value indicate endstage renal , pulmonary cardiac disease Known HIV infection Concurrent alcohol use 14 drink ( 140g ethanol ) men 7 drink ( 70g ethanol ) woman per week ( drink count 10g ethanol ) History drug alcohol abuse within 2 month prior dose Use prohibited medication ( section 4.8 ) Donation blood last 60 day history blood loss exceed 300 mL within last 3 month Suspicion evidence subject trustworthy reliable Suspicion evidence subject able make free consent understand information regard Significant side effect prior liver biopsy ( e.g . anxiety require premedication ) biopsy ( e.g . pain require i.v . pain medication , bleed require medical intervention ) General females Positive pregnancy test Premenopausal woman use appropriate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>